DOP2003000614A - Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole - Google Patents

Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole

Info

Publication number
DOP2003000614A
DOP2003000614A DO2003000614A DO2003000614A DOP2003000614A DO P2003000614 A DOP2003000614 A DO P2003000614A DO 2003000614 A DO2003000614 A DO 2003000614A DO 2003000614 A DO2003000614 A DO 2003000614A DO P2003000614 A DOP2003000614 A DO P2003000614A
Authority
DO
Dominican Republic
Prior art keywords
bencimidazol
rented
derivatives
mek inhibitors
compounds
Prior art date
Application number
DO2003000614A
Other languages
English (en)
Spanish (es)
Inventor
Eli M Walllace
Joe P Lyssikatos
Allison L Marlow
T Brian Hurley
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of DOP2003000614A publication Critical patent/DOP2003000614A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DO2003000614A 2002-03-13 2003-03-13 Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole DOP2003000614A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36416402P 2002-03-13 2002-03-13

Publications (1)

Publication Number Publication Date
DOP2003000614A true DOP2003000614A (es) 2009-09-30

Family

ID=28041882

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2003000614A DOP2003000614A (es) 2002-03-13 2003-03-13 Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole

Country Status (18)

Country Link
US (2) US20030216460A1 (OSRAM)
EP (1) EP1482944A4 (OSRAM)
JP (1) JP2005526076A (OSRAM)
KR (1) KR20040098013A (OSRAM)
CN (1) CN1652792A (OSRAM)
AR (1) AR038972A1 (OSRAM)
AU (1) AU2003220202A1 (OSRAM)
CA (1) CA2478534A1 (OSRAM)
CO (1) CO5611145A2 (OSRAM)
DO (1) DOP2003000614A (OSRAM)
IL (1) IL163996A0 (OSRAM)
MX (1) MXPA04008894A (OSRAM)
PA (1) PA8569201A1 (OSRAM)
PL (1) PL378635A1 (OSRAM)
RU (1) RU2300528C2 (OSRAM)
TW (1) TW200406203A (OSRAM)
UA (1) UA76837C2 (OSRAM)
WO (1) WO2003077855A2 (OSRAM)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI338685B (en) 2002-03-13 2011-03-11 Array Biopharma Inc N3 alkylated benzimid azole derivatives as mek inhibitors
US7235537B2 (en) * 2002-03-13 2007-06-26 Array Biopharma, Inc. N3 alkylated benzimidazole derivatives as MEK inhibitors
DE602004023207D1 (de) 2003-07-24 2009-10-29 Warner Lambert Co Benzimidazol-derivate als mek-hemmer
US7538120B2 (en) 2003-09-03 2009-05-26 Array Biopharma Inc. Method of treating inflammatory diseases
US7144907B2 (en) * 2003-09-03 2006-12-05 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
AR046411A1 (es) 2003-09-22 2005-12-07 S Bio Pte Ltd Derivados de bencimidazol. aplicaciones farmaceuticas
US7732616B2 (en) * 2003-11-19 2010-06-08 Array Biopharma Inc. Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof
AU2004293436B2 (en) 2003-11-19 2010-12-09 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
US7517994B2 (en) * 2003-11-19 2009-04-14 Array Biopharma Inc. Heterocyclic inhibitors of MEK and methods of use thereof
PH12012501891A1 (en) * 2003-11-21 2013-09-02 Array Biopharma Inc Akt protein kinase inhibitors
EP1699477A2 (en) * 2003-12-11 2006-09-13 Theravance, Inc. Compositions for use in the treatment of mutant receptor tyrosine kinase driven cellular proliferative diseases
MX2007004781A (es) 2004-10-20 2007-05-11 Applied Research Systems Derivados de 3-arilamino piridina.
CA2586796A1 (en) * 2004-12-01 2006-06-08 Laboratoires Serono S.A. [1,2,4]triazolo[4,3-a]pyridine derivatives for the treatment of hyperproliferative diseases
KR20080019236A (ko) * 2005-05-18 2008-03-03 어레이 바이오파마 인크. Ｍｅｋ의 헤테로시클릭 억제제 및 그의 사용 방법
ES2567133T3 (es) 2005-06-23 2016-04-20 Array Biopharma, Inc. Proceso para preparar compuestos de benzoimidazol
US8101799B2 (en) 2005-07-21 2012-01-24 Ardea Biosciences Derivatives of N-(arylamino) sulfonamides as inhibitors of MEK
SI1934174T1 (sl) * 2005-10-07 2011-08-31 Exelixis Inc Inhibitorji MEK in postopki za njihovo uporabo
CN101341132A (zh) * 2005-12-21 2009-01-07 阿斯利康(瑞典)有限公司 作为mek抑制剂用于治疗癌症的6-(4-溴-2-氯-苯基氨基)-7-氟-n-(2-羟基乙氧基)-3-甲基-3h-苯并咪唑-5-甲酰胺的甲苯磺酸盐
GB0601962D0 (en) 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
ATE532789T1 (de) 2006-07-06 2011-11-15 Array Biopharma Inc Dihydrothienopyrimidine als akt-proteinkinase- inhibitoren
US8329701B2 (en) 2006-07-06 2012-12-11 Array Biopharma Inc. Dihydrofuro pyrimidines as AKT protein kinase inhibitors
US8063050B2 (en) * 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
NZ573979A (en) 2006-07-06 2012-02-24 Array Biopharma Inc Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CN101583616B (zh) * 2006-08-21 2012-05-30 健泰科生物技术公司 氮杂苯并噻吩基化合物及使用方法
EP2069359B1 (en) * 2006-08-21 2014-11-12 Genentech, Inc. Aza-benzothiophenyl compounds and methods of use
KR101428116B1 (ko) * 2006-08-21 2014-08-07 제넨테크, 인크. 아자-벤조푸라닐 화합물 및 사용 방법
AU2007334402B2 (en) 2006-12-14 2014-02-13 Exelixis, Inc. Methods of using MEK inhibitors
JO2985B1 (ar) 2006-12-20 2016-09-05 Takeda Pharmaceuticals Co مثبطات كينازmapk/erk
EP2164850B1 (en) 2007-06-12 2016-01-13 Genentech, Inc. N-substituted azaindoles and methods of use
ES2551352T3 (es) 2007-07-05 2015-11-18 Array Biopharma, Inc. Pirimido ciclopentanos útiles para el tratamiento de enfermedades inflamatorias o hiperproliferativas
US8846683B2 (en) 2007-07-05 2014-09-30 Array Biopharma, Inc. Pyrimidyl cyclopentanes as Akt protein kinase inhibitors
US9409886B2 (en) 2007-07-05 2016-08-09 Array Biopharma Inc. Pyrimidyl cyclopentanes as AKT protein kinase inhibitors
MX2009014013A (es) 2007-07-05 2010-01-28 Array Biopharma Inc Pirimidil ciclopentanos como inhibidores de la proteina cinasa akt.
GB0714384D0 (en) 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
ES2456966T3 (es) 2007-11-12 2014-04-24 Takeda Pharmaceutical Company Limited Inhibidores de MAPK/ERK cinasa
NZ585306A (en) 2007-12-19 2012-05-25 Genentech Inc 8-Anilinoimidazopyridines and their use as anti-cancer and/or anti-inflammatory agents
EP2690101B1 (en) * 2007-12-19 2015-06-24 Genentech, Inc. 5-Anilinoimidazopyridines and Methods of Use
CA2708176A1 (en) 2007-12-21 2009-07-02 Genentech, Inc. Azaindolizines and methods of use
EP2240455B1 (en) * 2008-01-09 2012-12-26 Array Biopharma, Inc. Hydroxylated pyrimidyl cyclopentane as akt protein kinase inhibitor
ES2422733T3 (es) 2008-01-09 2013-09-13 Array Biopharma Inc Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
EP2240494B1 (en) 2008-01-21 2016-03-30 UCB Biopharma SPRL Thieno-pyridine derivatives as mek inhibitors
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
PE20110570A1 (es) 2008-07-01 2011-08-26 Genentech Inc Heterociclos biciclicos sustituidos
CA2727252A1 (en) * 2008-07-01 2010-01-07 Genentech, Inc. Isoindolone derivatives as mek kinase inhibitors and methods of use
MY151342A (en) 2008-08-04 2014-05-15 Merck Patent Gmbh Phenylamino isonicotinamide compounds
WO2010051933A2 (en) 2008-11-10 2010-05-14 Bayer Schering Pharma Aktiengesellschaft Substituted sulphonamido phenoxybenzamides
JP5651125B2 (ja) 2008-12-10 2015-01-07 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Ｍｅｋ阻害剤に対する耐性を付与するｍｅｋ突然変異
EP2491015A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
EP2491014A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted halophenoxybenzamide derivatives
EP2491016A1 (en) 2009-10-21 2012-08-29 Bayer Pharma Aktiengesellschaft Substituted benzosulphonamides
ES2576061T3 (es) 2010-02-25 2016-07-05 Dana-Farber Cancer Institute, Inc. Mutaciones de BRAF que confieren resistencia a inhibidores de BRAF
EP2545187B1 (en) 2010-03-09 2018-09-05 Dana-Farber Cancer Institute, Inc. Methods of diagnosing and treating cancer in patients having or developing resistance to a first cancer therapy
MA34591B1 (fr) 2010-10-06 2013-10-02 Glaxosmithkline Llc Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase
EP2632899A1 (en) 2010-10-29 2013-09-04 Bayer Intellectual Property GmbH Substituted phenoxypyridines
TR201815685T4 (tr) 2011-04-01 2018-11-21 Genentech Inc Kanser tedavisi için akt ve mek inhibe edici bileşiklerin kombinasyonları.
SG10201504303SA (en) 2011-04-01 2015-07-30 Genentech Inc Combinations Of AKT Inhibitor Compounds And Chemotherapeutic Agents, And Methods Of Use
EP2714037B1 (en) 2011-05-25 2016-07-13 Université Paris Descartes Erk inhibitors for use in treating spinal muscular atrophy
WO2013082511A1 (en) 2011-12-02 2013-06-06 Genentech, Inc. Methods for overcoming tumor resistance to vegf antagonists
CN103204827B (zh) 2012-01-17 2014-12-03 上海科州药物研发有限公司 作为蛋白激酶抑制剂的苯并噻二唑化合物及其制备方法和用途
WO2013169858A1 (en) 2012-05-08 2013-11-14 The Broad Institute, Inc. Diagnostic and treatment methods in patients having or at risk of developing resistance to cancer therapy
EP2854779A1 (en) 2012-05-31 2015-04-08 Bayer Pharma Aktiengesellschaft Biomarkers for determining effective response of treatments of hepatocellular carcinoma (hcc) patients
BR112015008113B1 (pt) 2012-10-12 2022-05-24 Exelixis, Inc. Novo processo para preparar compostos para uso no tratamento de câncer
EP2976106B1 (en) 2013-03-21 2021-04-14 Array BioPharma Inc. Combination therapy comprising a b-raf inhibitor and a second inhibitor
WO2015038704A1 (en) 2013-09-11 2015-03-19 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Compositions for preparing cardiomyocytes
CN105384754B (zh) * 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
US20190008859A1 (en) 2015-08-21 2019-01-10 Acerta Pharma B.V. Therapeutic Combinations of a MEK Inhibitor and a BTK Inhibitor
AR108257A1 (es) 2016-05-02 2018-08-01 Mei Pharma Inc Formas polimórficas de 3-[2-butil-1-(2-dietilamino-etil)-1h-bencimidazol-5-il]-n-hidroxi-acrilamida y usos de las mismas
WO2019096112A1 (zh) * 2017-11-14 2019-05-23 深圳市塔吉瑞生物医药有限公司 一种取代的苯并咪唑化合物及包含该化合物的组合物
KR20210142154A (ko) 2019-03-21 2021-11-24 옹쎄오 암 치료를 위한 키나제 억제제와 조합된 dbait 분자
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4346826A4 (en) 2021-05-27 2025-04-30 Mirati Therapeutics, Inc. COMBINATION THERAPIES
TW202342018A (zh) 2022-03-04 2023-11-01 美商奇奈特生物製藥公司 Mek激酶抑制劑
WO2025073765A1 (en) 2023-10-03 2025-04-10 Institut National de la Santé et de la Recherche Médicale Methods of prognosis and treatment of patients suffering from melanoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5502187A (en) * 1992-04-03 1996-03-26 The Upjohn Company Pharmaceutically active bicyclic-heterocyclic amines
US5525625A (en) * 1995-01-24 1996-06-11 Warner-Lambert Company 2-(2-Amino-3-methoxyphenyl)-4-oxo-4H-[1]benzopyran for treating proliferative disorders
US6469009B1 (en) * 1996-04-08 2002-10-22 Ucb, S.A. Pharmaceutical compositions for the treatment of rhinitis
US6506798B1 (en) * 1997-07-01 2003-01-14 Warner-Lambert Company 4-Arylamino, 4-aryloxy, and 4-arylthio diarylamines and derivatives thereof as selective MEK inhibitors
US6821963B2 (en) * 1997-07-01 2004-11-23 Warner-Lambert Company 4-Bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as MEK inhibitors
US6440966B1 (en) * 1999-01-13 2002-08-27 Warner-Lambert Company Benzenesulfonamide derivatives and their use as MEK inhibitors
IL144214A0 (en) * 1999-01-13 2002-05-23 Warner Lambert Co Benzoheterocycles and their use as mek inhibitors
CN1358094A (zh) * 1999-07-16 2002-07-10 沃尼尔·朗伯公司 用mek抑制剂治疗慢性疼痛的方法

Also Published As

Publication number Publication date
AR038972A1 (es) 2005-02-02
WO2003077855A2 (en) 2003-09-25
TW200406203A (en) 2004-05-01
CO5611145A2 (es) 2006-02-28
EP1482944A4 (en) 2006-04-19
PA8569201A1 (es) 2004-05-21
IL163996A0 (en) 2005-12-18
CA2478534A1 (en) 2003-09-25
EP1482944A2 (en) 2004-12-08
WO2003077855A3 (en) 2004-03-04
CN1652792A (zh) 2005-08-10
MXPA04008894A (es) 2005-06-20
AU2003220202A1 (en) 2003-09-29
JP2005526076A (ja) 2005-09-02
RU2300528C2 (ru) 2007-06-10
RU2004127925A (ru) 2005-05-27
US20030216460A1 (en) 2003-11-20
KR20040098013A (ko) 2004-11-18
PL378635A1 (pl) 2006-05-15
US20060106225A1 (en) 2006-05-18
UA76837C2 (uk) 2006-09-15

Similar Documents

Publication Publication Date Title
DOP2003000614A (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole
DOP2003000613A (es) Derivados de bencimidazol n3 alquilado como inhibidores de mek (n3 alkylated benzimidazole derivatives as mek inhibitors)
BRPI0413152A (pt) derivados de benzimidazol alquilado por n3 como inibidores de mek
EA200700902A1 (ru) 3-ариламинопиридиновые производные
TW200526658A (en) Heterocyclic inhibitors of MEK and methods of use thereof
CR10277A (es) Pirazolquinolonas como potentes inhibidores de parp
CR10288A (es) Pirazoles como inhibidores de la 11-beta-hsd1
ECSP11011151A (es) Compuestos purina
ECSP078013A (es) Inhibidores heterocíclicos de mek y métodos de uso de ellos
CL2011000777A1 (es) Compuestos derivados de imidazopiridazina, inhibidor de proteína quinasa; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer, psoriasis, artritis reumatoide, angiogenesis, entre otras.
UY28572A1 (es) Compuestos novedosos
MXPA05012573A (es) Derivados de pirazolo-quinazolina, procedimiento para su preparacion y su uso como inhibidores de cinasa.
ECSP099445A (es) Quinazolinas para la inhibición de pdk1
EA200802050A1 (ru) Новые гетероарилзамещенные ариламинопиридиновые производные в качестве мек ингибиторов
ECSP088561A (es) Derivados de pirimidinil-aril-urea que son inhibidores de fgf
CL2011000589A1 (es) Compuestos derivados de pirrolidin-2-carboxamida, inhibidores de la interaccion p53-mdm2; composicion farmaceutica que los comprende; y su uso en la preparacion de medicamentos utiles para el tratamiento del cancer.
SV2002000478A (es) Derivados de tiofeno utiles como anticancerosos ref. pc10795aagl/bb
ECSP056246A (es) DERIVADOS DE PIRROLO [3,4-c]PIRAZOL ACTIVOS COMO INHIBIDORES DE QUINASA
UY31457A1 (es) Derivados acidos de cicloalquilamino
UY28745A1 (es) Nuevos compuestos
ECSP10010248A (es) Inhibidores de cinesina como productos terapéuticos para el cáncer
ECSP066349A (es) Inhibidores de transferasa de proteína de farnesilo novedosos como agentes antitumorales
CU20120085A7 (es) Derivados de sulfamidas heterocíclicas
UY27770A1 (es) Imidazolinilmetil aralquilsulfonamidas
GT200800296A (es) Derivados de ácido fenilacético